Repligen Corp is a leading pharmaceutical company based in the United States. With a low risk ESG score of 15.9, Repligen specializes in developing and commercializing bioprocessing technologies for manufacturing biological drugs. Serving a wide range of customers globally, including life science companies and biopharmaceutical giants, Repligen's products are marketed worldwide through direct commercial channels and strategic partnerships. The majority of the company's revenue comes from North America.